Paragon Biosciences
Paragon Biosciences is a global healthcare company committed to accelerating biomedical research. It solves complex challenges by advancing science. Paragon focuses on four areas of life science innovation including artificial intelligence, gene therapy, synthetic biology, and biopharmaceuticals. Its current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies in development. Paragon stands at the intersection of human need, life science, and company creation. The company was founded in 2010 and is headquartered in Northbrook, Illinois.
Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need. It was founded in 2015 and headquartered in Pennsylvania, United States.
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders. The company's first development candidate Ecopipam, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. Emalex Biosciences was founded in 2018 by Jeff Aronin.
Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need. It was founded in 2015 and headquartered in Pennsylvania, United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.